These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38858607)

  • 1. SGLT2 regulates immune-mediated senolysis.
    Guo G; Amor C
    Nat Aging; 2024 Jul; 4(7):909-910. PubMed ID: 38858607
    [No Abstract]   [Full Text] [Related]  

  • 2. The Brains Behind SGLT2 Inhibition.
    Schlögl H; Stumvoll M
    Diabetes Care; 2022 Feb; 45(2):273-275. PubMed ID: 35050363
    [No Abstract]   [Full Text] [Related]  

  • 3. Proving SGLT2 Inhibitor-Mediated Improvement in Cardiomyocyte Energetics: Beyond a Reasonable Doubt?
    Filipp M; Shah SJ
    Circ Heart Fail; 2024 Jun; 17(6):e011646. PubMed ID: 38847114
    [No Abstract]   [Full Text] [Related]  

  • 4. SGLT2 inhibitors: not every drug has the same effect.
    Staruschenko A
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1039-F1040. PubMed ID: 38695073
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
    Mordi IR; Lang CC
    Heart Fail Clin; 2022 Oct; 18(4):529-538. PubMed ID: 36216483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging.
    Katsuumi G; Shimizu I; Suda M; Yoshida Y; Furihata T; Joki Y; Hsiao CL; Jiaqi L; Fujiki S; Abe M; Sugimoto M; Soga T; Minamino T
    Nat Aging; 2024 Jul; 4(7):926-938. PubMed ID: 38816549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies.
    Takada S; Sabe H; Kinugawa S
    Am J Physiol Heart Circ Physiol; 2022 Feb; 322(2):H117-H128. PubMed ID: 34860594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
    Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
    Kume S; Packer M
    Kidney Int; 2024 Jun; 105(6):1172-1176. PubMed ID: 38777403
    [No Abstract]   [Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors.
    Zhao X; Sun B; Zheng H; Liu J; Qian L; Wang X; Lou H
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2201-2205. PubMed ID: 29764742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming.
    Gao YM; Feng ST; Wen Y; Tang TT; Wang B; Liu BC
    EBioMedicine; 2022 Sep; 83():104215. PubMed ID: 35973390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
    Vallon V; Verma S
    Annu Rev Physiol; 2021 Feb; 83():503-528. PubMed ID: 33197224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
    Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
    Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between SGLT2 and systemic blood pressure regulation.
    Ahwin P; Martinez D
    Hypertens Res; 2024 Aug; 47(8):2094-2103. PubMed ID: 38783146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?
    Wichaiyo S; Saengklub N
    Heart Fail Rev; 2022 Nov; 27(6):1973-1990. PubMed ID: 35179683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice.
    Miyata KN; Lo CS; Zhao S; Liao MC; Pang Y; Chang SY; Peng J; Kretzler M; Filep JG; Ingelfinger JR; Zhang SL; Chan JSD
    Clin Sci (Lond); 2021 Apr; 135(7):943-961. PubMed ID: 33822013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes.
    Čertíková Chábová V; Zakiyanov O
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
    Thomson SC; Vallon V
    Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients.
    Kubica J; Kubica A; Grzelakowska K; Stolarek W; Grąbczewska Z; Michalski P; Niezgoda P; Bartuś S; Budaj A; Dąbrowski M; Drożdż J; Gellert R; Jaguszewski MJ; Jankowski P; Legutko J; Lesiak M; Leszek P; Małyszko J; Mitkowski P; Nessler J; Pawlaczyk K; Siller-Matula J; Stompór T; Wolnik B; Navarese EP
    Cardiol J; 2023; 30(1):143-149. PubMed ID: 34708866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.